Jyong Biotech (NASDAQ:MENS) Shares Gap Down - Time to Sell?

Key Points

• Jyong Biotech shares gapped down significantly from a previous closing price of $55.24 to an opening price of $53.47, last trading at $55.00.
• Analysts have mixed sentiments about the stock, with one upgrading it to a "hold" while another maintained a "sell" rating, leading to an average rating of "sell" across the board.
• The company's 50-day moving average currently stands at $50.06, indicating potential volatility in the stock price.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $55.24, but opened at $53.47. Jyong Biotech shares last traded at $55.00, with a volume of 5,354 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Jyong Biotech to a "hold" rating in a research note on Monday, June 30th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Jyong Biotech in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of "Sell".

Jyong Biotech Stock Performance

The stock's 50-day moving average is $50.06.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.